Bio-Techne Corporation

DB:TE1 Stock Report

Market Cap: €9.5b

Bio-Techne Valuation

Is TE1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of TE1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: TE1 (€60.5) is trading below our estimate of future cash flow value (€62.32)

Significantly Below Future Cash Flow Value: TE1 is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TE1?

Key metric: As TE1 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for TE1. This is calculated by dividing TE1's market cap by their current earnings.
What is TE1's PE Ratio?
PE Ratio142.7x
EarningsUS$77.95m
Market CapUS$11.12b

Price to Earnings Ratio vs Peers

How does TE1's PE Ratio compare to its peers?

The above table shows the PE ratio for TE1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average52x
SRT3 Sartorius
135.1x23.43%€15.6b
1SXP SCHOTT Pharma KGaA
15.6x7.61%€2.2b
GXI Gerresheimer
40.4x41.71%€863.5m
DMP Dermapharm Holding
16.8x11.48%€1.9b
TE1 Bio-Techne
142.7x23.24%€11.1b

Price-To-Earnings vs Peers: TE1 is expensive based on its Price-To-Earnings Ratio (142.7x) compared to the peer average (49.7x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does TE1's PE Ratio compare vs other companies in the European Life Sciences Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
TE1 142.7xIndustry Avg. 37.2xNo. of Companies3PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: TE1 is expensive based on its Price-To-Earnings Ratio (142.7x) compared to the Global Life Sciences industry average (37.2x).

Price to Earnings Ratio vs Fair Ratio

What is TE1's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TE1 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio142.7x
Fair PE Ratio26.2x

Price-To-Earnings vs Fair Ratio: TE1 is expensive based on its Price-To-Earnings Ratio (142.7x) compared to the estimated Fair Price-To-Earnings Ratio (26.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TE1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€60.50
€60.10
-0.66%
8.49%€68.69€51.52n/a12
Jan ’27€49.60
€59.29
+19.54%
6.72%€63.83€51.07n/a12
Dec ’26€54.50
€59.70
+9.55%
6.83%€64.74€51.79n/a12
Nov ’26€54.00
€58.49
+8.32%
8.23%€64.67€50.88n/a12
Oct ’26€51.00
€56.11
+10.02%
10.32%€64.09€45.29n/a12
Sep ’26€45.80
€55.90
+22.05%
10.15%€64.19€45.36n/a13
Aug ’26€47.00
€58.21
+23.85%
11.95%€70.02€48.14n/a14
Jul ’26€43.80
€57.12
+30.41%
16.07%€76.41€43.30n/a13
Jun ’26€42.40
€61.00
+43.87%
17.34%€79.27€44.92n/a13
May ’26€43.80
€70.07
+59.97%
15.36%€83.52€44.84n/a12
Apr ’26€52.50
€77.74
+48.08%
10.94%€88.06€63.03n/a13
Mar ’26€59.00
€81.94
+38.88%
9.15%€91.13€65.23n/a13
Feb ’26€70.50
€81.44
+15.51%
6.70%€90.57€71.51n/a13
Jan ’26€69.50
€81.82
+17.72%
6.72%€91.16€71.97€49.6013
Dec ’25€71.00
€78.38
+10.39%
6.72%€87.34€68.96€54.5013
Nov ’25€68.50
€78.38
+14.42%
6.72%€87.34€68.96€54.0013
Oct ’25€71.00
€75.07
+5.74%
8.27%€85.83€58.73€51.0013
Sep ’25€66.50
€75.22
+13.12%
9.17%€86.56€59.23€45.8013
Aug ’25€76.00
€76.76
+1.00%
9.20%€87.19€59.66€47.0013
Jul ’25€66.00
€77.79
+17.86%
9.66%€87.96€60.18€43.8013
Jun ’25€70.50
€77.79
+10.34%
9.66%€87.96€60.18€42.4013
May ’25€59.00
€76.12
+29.01%
10.33%€88.85€60.79€43.8011
Apr ’25€65.00
€74.47
+14.57%
8.61%€88.07€60.26€52.5013
Mar ’25€68.00
€74.47
+9.51%
8.61%€88.07€60.26€59.0013
Feb ’25€63.00
€74.16
+17.71%
9.19%€87.40€59.80€70.5012
Jan ’25€70.50
€71.93
+2.02%
11.64%€86.05€58.88€69.5013
€59.33
Fair Value
2.0% overvalued intrinsic discount
12
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/22 21:36
End of Day Share Price 2026/01/21 00:00
Earnings2025/09/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Techne Corporation is covered by 25 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Catherine Ramsey SchulteBaird
Robert WassermanBenchmark Company